6 results on '"Federica de Cicco"'
Search Results
2. Pathology Reporting in Neuroendocrine Neoplasms of the Digestive System: Everything You Always Wanted to Know but Were Too Afraid to Ask
- Author
-
Manuela Albertelli, Federica Grillo, Fabio Lo Calzo, Giulia Puliani, Carmen Rainone, Annamaria Anita Livia Colao, Antongiulio Faggiano, NIKE group, Barbara Altieri, Luigi Barrea, Filomena Bottiglieri, Severo Campione, Federica De Cicco, Sergio Di Molfetta, Alessandra Dicitore, Carlotta Dolci, Tiziana Feola, Giuseppe Fanciulli, Diego Ferone, Francesco Ferraù, Marco Gallo, Elisa Giannetta, Erika Grossrubatscher, Elia Guadagno, Valentina Guarnotta, Andrea M. Isidori, Andrea Lania, Andrea Lenzi, Pasquale Malandrino, Erika Messina, Roberta Modica, Giovanna Muscogiuri, Luca Pes, Genoveffa Pizza, Riccardo Pofi, Paola Razzore, Laura Rizza, Manila Rubino, Rosa Maria Ruggieri, Emilia Sbardella, Franz Sesti, Mary Anna Venneri, Giovanni Vitale, and Maria Chiara Zatelli
- Subjects
neuroendocrine neoplasms (NENs) ,neuroendocrine classification ,immunohistochemistry ,pathology ,morphology ,grade ,Diseases of the endocrine glands. Clinical endocrinology ,RC648-665 - Abstract
During the 5th NIKE (Neuroendocrine tumors Innovation in Knowledge and Education) meeting, held in Naples, Italy, in May 2019, discussions centered on the understanding of pathology reports of gastroenetropancreactic neuroendocrine neoplasms. In particular, the main problem concerned the difficulty that clinicians experience in extrapolating relevant information from neuroendocrine tumor pathology reports. During the meeting, participants were asked to identify and rate issues which they have encountered, for which the input of an expert pathologist would have been appreciated. This article is a collection of the most rated questions and relative answers, focusing on three main topics: 1) morphology and classification; 2) Ki67 and grading; 3) immunohistochemistry. Patient management should be based on multidisciplinary decisions, taking into account clinical and pathology-related features with clear comprehension between all health care professionals. Indeed, pathologists require clinical details and laboratory findings when relevant, while clinicians require concise and standardized reports. In keeping with this last statement, the minimum requirements in pathology datasets are provided in this paper and should be a baseline for all neuroendocrine tumor professionals.
- Published
- 2021
- Full Text
- View/download PDF
3. Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management
- Author
-
Giuseppe Fanciulli, Sergio Di Molfetta, Andrea Dotto, Tullio Florio, Tiziana Feola, Annamaria Colao, Antongiulio Faggiano, NIKE Group, Manuela Albertelli, Barbara Altieri, Luigi Barrea, Filomena Bottiglieri, Severo Campione, Federica de Cicco, Alessandra Dicitore, Diego Ferone, Francesco Ferraù, Erika Grossrubatscher, Marco Gallo, Elisa Giannetta, Federica Grillo, Elia Guadagno, Valentina Guarnotta, Andrea M. Isidori, Andrea Lania, Andrea Lenzi, Fabio Lo Calzo, Pasquale Malandrino, Erika Messina, Roberta Modica, Giovanna Muscogiuri, Genoveffa Pizza, Riccardo Pofi, Giulia Puliani, Carmen Rainone, Paola Razzore, Laura Rizza, Manila Rubino, Rosa Maria Ruggieri, Emilia Sbardella, Franz Sesti, Mary Anna Venneri, Giovanni Vitale, Maria Chiara Zatelli, Fanciulli, G., Di Molfetta, S., Dotto, A., Florio, T., Feola, T., Colao, A., and Faggiano, A.
- Subjects
Oncology ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,Immune checkpoint inhibitors ,immune checkpoint inhibitor ,Ipilimumab ,Pembrolizumab ,Diseases of the endocrine glands. Clinical endocrinology ,immune checkpoint inhibitors ,Antineoplastic Agents, Immunological ,Endocrinology ,Internal medicine ,medicine ,antineoplastic agents ,Humans ,ipilimumab ,Lymph node ,nivolumab ,business.industry ,General Commentary ,Lymph Node ,Lymphatic Metastasi ,parathyroid carcinoma ,medicine.disease ,RC648-665 ,immunological ,medicine.anatomical_structure ,Parathyroid Neoplasms ,Parathyroid carcinoma ,Lymphatic Metastasis ,pembrolizumab ,Lymph Nodes ,Nivolumab ,business ,humans ,lymph nodes ,lymphatic metastasis ,antineoplastic agents, immunological ,parathyroid neoplasms ,medicine.drug ,Human - Published
- 2021
4. From microbiota toward gastro-enteropancreatic neuroendocrine neoplasms: Are we on the highway to hell?
- Author
-
Giulia Puliani, Andrea Lania, Fabio Lo Calzo, Valentina Guarnotta, Giuseppe Fanciulli, Alessandra Dicitore, Carmen Rainone, Annamaria Colao, Genoveffa Pizza, Manila Rubino, Giovanni Vitale, Severo Campione, Francesco Ferraù, Maria Chiara Zatelli, Mary Anna Venneri, Emilia Sbardella, Diego Ferone, Marco Gallo, Riccardo Pofi, Roberta Modica, Luigi Barrea, Erika Grossrubatscher, Federica Grillo, Antongiulio Faggiano, Franz Sesti, Rosa Maria Ruggieri, Barbara Altieri, Erika Messina, Luca Pes, P. Razzore, Nike, Andrea M. Isidori, Sergio Di Molfetta, Pasquale Malandrino, Andrea Lenzi, Manuela Albertelli, Tiziana Feola, Laura Rizza, Giovanna Muscogiuri, Federica de Cicco, Filomena Bottiglieri, Elia Guadagno, Elisa Giannetta, Vitale G, Dicitore A, Barrea L, Sbardella E, Razzore P, Campione S, Faggiano A, Colao A, NIKE, Albertelli M, Altieri B, Bottiglieri F, De Cicco F, Di Molfetta S, Fanciulli G, Feola T, Ferone D, Ferraù F, Gallo M, Giannetta E, Grillo F, Grossrubatscher E, Guadagno E, Guarnotta V, Isidori AM, Lania A, Lenzi A, Calzo FL, Malandrino P, Messina E, Modica R, Muscogiuri G, Pes L, Pizza G, Pofi R, Puliani G, Rainone C, Rizza L, Rubino M, Ruggieri RM, Sesti F, Venneri MA, Zatelli MC., Vitale, G., Dicitore, A., Barrea, L., Sbardella, E., Razzore, P., Campione, S., Faggiano, A., Colao, A., Albertelli, M., Altieri, B., Bottiglieri, F., De Cicco, F., Di Molfetta, S., Fanciulli, G., Feola, T., Ferone, D., Ferrau, F., Gallo, M., Giannetta, E., Grillo, F., Grossrubatscher, E., Guadagno, E., Guarnotta, V., Isidori, A. M., Lania, A., Lenzi, A., Calzo, F. L., Malandrino, P., Messina, E., Modica, R., Muscogiuri, G., Pes, L., Pizza, G., Pofi, R., Puliani, G., Rainone, C., Rizza, L., Rubino, M., Ruggieri, R. M., Sesti, F., Venneri, M. A., and Zatelli, M. C.
- Subjects
Endocrinology, Diabetes and Metabolism ,Tumor microenvironment ,Biology ,Gut flora ,Neuroendocrine tumors ,medicine.disease_cause ,digestive system ,Article ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Immune system ,Neuroendocrine tumor ,Gastro ,medicine ,Humans ,Cytokine ,030304 developmental biology ,Gastrointestinal Neoplasms ,Inflammation ,0303 health sciences ,Microbiota ,digestive, oral, and skin physiology ,medicine.disease ,biology.organism_classification ,Cytokines ,Gastrointestinal Microbiome ,030220 oncology & carcinogenesis ,Immunology ,Dysbiosis ,Carcinogenesis ,Drug metabolism - Abstract
Gut microbiota is represented by different microorganisms that colonize the intestinal tract, mostly the large intestine, such as bacteria, fungi, archaea and viruses. The gut microbial balance has a key role in several functions. It modulates the host’s metabolism, maintains the gut barrier integrity, participates in the xenobiotics and drug metabolism, and acts as protection against gastro-intestinal pathogens through the host’s immune system modulation. The impaired gut microbiota, called dysbiosis, may be the result of an imbalance in this equilibrium and is linked with different diseases, including cancer. While most of the studies have focused on the association between microbiota and gastrointestinal adenocarcinomas, very little is known about gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs). In this review, we provide an overview concerning the complex interplay between gut microbiota and GEP NENs, focusing on the potential role in tumorigenesis and progression in these tumors.
- Published
- 2020
5. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid
- Author
-
Gabriella, Misso, Manuela, Porru, Stoppacciaro, Antonella, Maria, Castellano, Federica De Cicco, Carlo, Leonetti, Daniele, Santini, Michele, Caraglia, Santini, Daniele, Misso, Gabriella, Porru, M, Stoppacciaro, A, Castellano, M, De Cicco, F, Leonetti, C, Santini, D, and Caraglia, Michele
- Subjects
Pathology ,Cancer Research ,Angiogenesis ,Angiogenesis Inhibitors ,Humanized antibody ,Neovascularization ,Mice ,zoledronic acid ,angiogenesis ,huvec ,Mice, Inbred BALB C ,biology ,Bone Density Conservation Agents ,Diphosphonates ,Neovascularization, Pathologic ,Imidazoles ,denosumab ,breast cancer ,acid 10.4161/cbt.22274 ,anticancer ,rankl ,zoledronic ,Angiogenesi ,Denosumab ,Diphosphonate ,Oncology ,RANKL ,Molecular Medicine ,Female ,medicine.symptom ,Breast Neoplasm ,medicine.drug ,Angiogenesis Inhibitor ,Human ,Research Paper ,medicine.medical_specialty ,Bone Density Conservation Agent ,Xenograft Model Antitumor Assay ,Cell Survival ,Human Umbilical Vein Endothelial Cell ,Mice, Nude ,Bone Neoplasms ,Breast Neoplasms ,Bone Neoplasm ,Antibodies, Monoclonal, Humanized ,In vivo ,Cell Line, Tumor ,medicine ,Human Umbilical Vein Endothelial Cells ,Animals ,Humans ,Imidazole ,Pharmacology ,Matrigel ,business.industry ,Animal ,RANK Ligand ,Xenograft Model Antitumor Assays ,In vitro ,Cancer research ,biology.protein ,business ,Neoplasm Transplantation - Abstract
""Denosumab (Dmab) and zoledronic acid (ZOL) are antiresorptive agents, with different mechanisms of action, that are indicated for delaying the onset of skeletal-related events in patients with bone metastases from solid tumors. Clinical and preclinical data suggest that ZOL may have also anti-angiogenic activity; however, the effects of Dmab (a fully humanized antibody against the receptor activator of nuclear factor kappa B ligand) on angiogenesis are largely unknown. The objective of this study was to compare the potential anti-angiogenic activity of Dmab with that of ZOL in preclinical models. Dmab (0.31 to 160 µM) had no effect on the viability of human MDA-MB-436 and CG5 breast cancer cells or human umbilical vein endothelial cells (HUVECs) and no effect on tubule formation or invasion of HUVECs. In contrast, ZOL (0.31 to 160 µM) decreased the viability of breast cancer and HUVECs in a time- and concentration-dependent manner, and also inhibited HUVEC tubule formation and invasion. In vivo, ZOL (100 µg\\\/kg s.c. twice weekly for 6 weeks) inhibited angiogenesis in Matrigel plugs and inhibited the growth and neo-angiogenesis of CG5 xenografts in athymic nude mice. In contrast, Dmab (100 µg\\\/kg s.c. twice weekly for 6 weeks) had no effect on Matrigel vascularization or xenograft growth in this model. These findings support the potential antiangiogenic and anticancer activity of ZOL in vitro and in vivo, and further suggest that Dmab does not have antiangiogenic activity. Additional studies are needed to elucidate the potential anticancer activity of Dmab."" Denosumab (Dmab) and zoledronic acid (ZOL) are antiresorptive agents, with different mechanisms of action, that are indicated for delaying the onset of skeletal-related events in patients with bone metastases from solid tumors. Clinical and preclinical data suggest that ZOL may have also anti-angiogenic activity; however, the effects of Dmab (a fully humanized antibody against the receptor activator of nuclear factor kappa B ligand) on angiogenesis are largely unknown. The objective of this study was to compare the potential anti-angiogenic activity of Dmab with that of ZOL in preclinical models. Dmab (0.31 to 160 μM) had no effect on the viability of human MDA-MB-436 and CG5 breast cancer cells or human umbilical vein endothelial cells (HUVECs) and no effect on tubule formation or invasion of HUVECs. In contrast, ZOL (0.31 to 160 μM) decreased the viability of breast cancer and HUVECs in a time- and concentration-dependent manner and also inhibited HUVEC tubule formation and invasion. In vivo, ZOL (20 μg/mouse three times a week for three consecutive weeks) inhibited angiogenesis in Matrigel plugs and inhibited the growth and neo-angiogenesis of CG5 xenografts in athymic nude mice. In contrast, Dmab (10 mg/kg twice a week for four consecutive weeks) had no effect on Matrigel vascularization or xenograft growth in this model. These findings support the potential antiangiogenic and anticancer activity of ZOL in vitro and in vivo and further suggest that Dmab does not have antiangiogenic activity. Additional studies are needed to elucidate the potential anticancer activity of Dmab. © 2012 Landes Bioscience.
- Published
- 2012
6. On and off-target effects of telomere uncapping G-quadruplex selective ligands based on pentacyclic acridinium salts
- Author
-
Erica Salvati, Chiara Cingolani, Annamaria Biroccio, Sara Iachettini, Mark S. Searle, Rupesh Nanjunda, Thomas P. Garner, Marc Geoffery Hummersone, Carlo Leonetti, Pasquale Zizza, Mark Frigerio, Ian Hutchinson, Federica De Cicco, Carmen D'Angelo, David Wilson, Angela Maria Rizzo, Malcolm F. G. Stevens, Maurizio D'Incalci, Manoj Munde, and Manuela Porru
- Subjects
Cancer Research ,Telomerase ,Anti-cancer therapy ,Guinea Pigs ,Biology ,G-quadruplex ,Ligands ,chemistry.chemical_compound ,Animals ,Humans ,Uncapping ,Cells, Cultured ,Cell Proliferation ,Telomere-binding protein ,Research ,Promoter ,Telomere targeting agents ,Telomere ,Small molecule ,G-Quadruplexes ,Oncology ,Biochemistry ,chemistry ,Acridines ,DNA - Abstract
Quadruplexes DNA are present in telomeric DNA as well as in several cancer-related gene promoters and hence affect gene expression and subsequent biological processes. The conformations of G4 provide selective recognition sites for small molecules and thus these structures have become important drug-design targets for cancer treatment. The DNA G-quadruplex binding pentacyclic acridinium salt RHPS4 (1) has many pharmacological attributes of an ideal telomere-targeting agent but has undesirable off-target liabilities. Notably a cardiovascular effect was evident in a guinea pig model, manifested by a marked and sustained increase in QTcB interval. In accordance with this, significant interaction with the human recombinant β2 adrenergic receptor, and M1, M2 and M3 muscarinic receptors was observed, together with a high inhibition of the hERG tail current tested in a patch clamp assay. Two related pentacyclic structures, the acetylamines (2) and (3), both show a modest interaction with β2 adrenergic receptor, and do not significatively inhibit the hERG tail current while demonstrating potent telomere on-target properties comparing closely with 1. Of the two isomers, the 2-acetyl-aminopentacycle (2) more closely mimics the overall biological profile of 1 and this information will be used to guide further synthetic efforts to identify novel variants of this chemotype, to maximize on-target and minimize off-target activities. Consequently, the improvement of toxicological profile of these compounds could therefore lead to the obtainment of suitable molecules for clinical development offering new pharmacological strategies in cancer treatment.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.